The German Breast Group conducts research into breast cancer, developing and implementing its own study concepts.
With the help of additional scientific research projects, we strive to gain further insights into this disease.
Further results from the prospective PANTHER trial focused on obese breast cancer patients treated with adjuvant tailored dose-dense chemotherapy versus standard treatment have been published in the Annals of Oncology.
Data of several GBG trials and translational research projects will be presented at the upcoming SABCS 2018 Congress, which will take place from 4-8 December in San Antonio, Texas, USA.
The survival analysis of patients with triple-negative and HER2-positive early breast cancer enrolled in the neoadjuvant GeparSixto (GBG 66) phase II trial have been published in the Annals of Oncology.
Data of several GBG trials and translational research projects will be presented at the upcoming ESMO 2018 Congress, which will take place from 19 to 23 October in Munich, Germany.
A statistical research study that aimed to develop an empirical model for predicting the magnitude of the treatment effects on survival endpoints based on the treatment effects on pathological complete response (pCR) has been published in the Contemporary Clinical Trials.
Every month, we present an interesting paper.
Große internationale Multicenter-Studie (TAXIS) vergleicht zwei chirurgische Therapiekonzepte bei Brustkrebs mit Lymphknotenbefall / Prof. Dr. Jörg Heil